French Regulators Fine Novo, Lilly Over GLP-1 Campaigns
French regulators have fined Novo Nordisk and Eli Lilly nearly €2 million for illegal advertising related to obesity medications. The fines were imposed for campaigns that indirectly promoted prescription GLP-1 receptor agonists, which is prohibited under French law. Both companies have expressed their intention to contest the fines and defend their marketing practices.
- ▪The National Agency for Medicines and Health Products Safety fined Novo Nordisk €1.78 million and Lilly €108,766.50.
- ▪The campaigns were found to mislead the public by suggesting that prescription obesity medications could be used for general weight loss.
- ▪Wegovy and Mounjaro are approved only as second-line treatments for obesity and cannot be advertised directly to the public.
Opening excerpt (first ~120 words) tap to expand
France’s National Agency for Medicines and Health Products Safety (ANSM) fined pharmaceutical companies Novo Nordisk and Eli Lilly and Company nearly €2 million for conducting obesity awareness campaigns classified as illegal, indirect advertising for prescription GLP-1 receptor agonists.The companies involved were Novo Nordisk and Eli Lilly and Company, manufacturers of prescription GLP-1 receptor agonist medications, particularly Wegovy and Mounjaro. On April 29, the agency imposed three financial penalties: two involving Novo Nordisk and one involving Lilly.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
